Clesitamig

Clesitamig is a DLL3/CD3/CD137 trispecific T cell engager, consisting of two CD3/CD137 dual-specific antigen-binding fragments (Fabs) and one additional DLL3 antigen-binding fragment (Fab). Clesitamig exhibits potent antitumor activity and can be used in research on tumors such as small cell lung cancer[1].